Solventum’s (SOLV) Overweight Rating Reaffirmed at Piper Sandler

Piper Sandler reissued their overweight rating on shares of Solventum (NYSE:SOLV) in a research report released on Friday morning,Benzinga reports. They currently have a $110.00 price objective on the stock, up from their prior price objective of $105.00.

A number of other research firms also recently weighed in on SOLV. Weiss Ratings raised shares of Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. KeyCorp lifted their price target on shares of Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Benchmark reissued a “buy” rating on shares of Solventum in a research note on Thursday, October 8th. Mizuho set a $113.00 price objective on shares of Solventum in a report on Thursday, August 6th. Finally, Stifel Nicolaus upped their price objective on shares of Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $90.27.

Solventum Stock Up 3.6%

Shares of SOLV stock traded up $3.17 during midday trading on Friday, reaching $90.34. 3,168,921 shares of the stock were exchanged, compared to its average volume of 1,109,088. Solventum has a 1 year low of $62.38 and a 1 year high of $94.16. The firm has a market cap of $15.38 billion, a PE ratio of 101.51, a price-to-earnings-growth ratio of 1.24 and a beta of 0.69. The company’s 50 day moving average is $87.73 and its two-hundred day moving average is $78.70. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, November 5th. The company reported $1.45 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.11. The company had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.93 billion. Solventum had a return on equity of 25.09% and a net margin of 17.26%. The firm’s revenue for the quarter was down 7.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.50 EPS. On average, equities research analysts predict that Solventum will post 7.21 EPS for the current year.

Institutional Investors Weigh In On Solventum

Hedge funds have recently added to or reduced their stakes in the stock. Wellington Grp LLC boosted its stake in Solventum by 50.2% in the 3rd quarter. Wellington Grp LLC now owns 16,539 shares of the company’s stock worth $1,458,000 after purchasing an additional 5,529 shares in the last quarter. Diversified Trust Co purchased a new position in Solventum in the third quarter worth about $214,000. Aberdeen Group plc raised its holdings in Solventum by 865.4% in the third quarter. Aberdeen Group plc now owns 61,369 shares of the company’s stock worth $5,410,000 after buying an additional 55,012 shares during the last quarter. Allworth Financial LP lifted its stake in shares of Solventum by 11.1% in the third quarter. Allworth Financial LP now owns 5,575 shares of the company’s stock worth $491,000 after buying an additional 557 shares in the last quarter. Finally, Fisher Asset Management LLC bought a new position in shares of Solventum in the third quarter worth approximately $239,000.

Trending Headlines about Solventum

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Solventum earned $1.45 per share on $1.95 billion in revenue, beating consensus estimates of $1.34–$1.35 per share and $1.93 billion in sales. The company raised its 2026 adjusted EPS guidance to $7.20–$7.30 and expects organic sales growth toward the high end of its 2.5%–3.0% range. Solventum Q3 results
• Positive Sentiment: Analysts lifted price targets: Piper Sandler raised its target to $110 and reaffirmed an overweight rating; Wells Fargo increased its target to $95 while retaining an equal-weight rating. Jefferies raised its target to $98. Piper Sandler rating
• Neutral Sentiment: The company said the 7% year-over-year sales decline (organic sales down 2.8%) reflected, in part, a temporary ERP transition effect: customers had placed advance orders in the prior quarter ahead of the system cutover. Solventum also reported that its separation process was more than 90% complete. Q3 earnings and ERP impact
• Negative Sentiment: Despite the quarterly beat, revenue fell 7% year over year and EPS was down from $1.50 a year ago, highlighting ongoing comparisons and execution risks. Quarterly earnings details

Solventum Company Profile

Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.